6:10 PM
 | 
Feb 11, 2009
 |  BC Extra  |  Clinical News

Ustekinumab meets psoriatic arthritis endpoint

Data from a Phase II trial showed that ustekinumab from Johnson & Johnson (NYSE:JNJ) met the primary endpoint of a greater proportion of...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >